US Patent Issued to Wyvern Pharmaceuticals on Sept. 16 for "Plasmid encoding a TLR3 and Fc fusion protein" (Canadian Inventor)

ALEXANDRIA, Va., Sept. 17 -- United States Patent no. 12,416,020, issued on Sept. 16, was assigned to Wyvern Pharmaceuticals Inc. (Calgary, Canada).

"Plasmid encoding a TLR3 and Fc fusion protein" was invented by Bradley G. Thompson (Calgary, Canada).

According to the abstract* released by the U.S. Patent & Trademark Office: "Loss of B cell tolerance and generation of autoreactive anti-nuclear antibodies are hallmarks of systemic lupus erythematosus (SLE) and lupus nephritis. Lupus nephritis is characterized by glomerular and tubulointerstitial inflammation often initiated by the renal glomerular deposition of anti-nuclear immune complexes which trigger subsequent activation of complement, macrophages/monocytes and other innate inflammato...